E88.3

Applicable To

• Tumor lysis syndrome spontaneous)

• Tumor lysis syndrome following antineoplastic drug chemotherapy

Clinical Information

• A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and t cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death.

• A condition that can occur after treatment of a fast-growing cancer, especially certain leukemias and lymphomas cancers of the blood). As tumor cells die, they break apart and release their contents into the blood. This causes a change in certain chemicals in the blood, which may cause damage to organs, including the kidneys, heart, and liver.

• A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.

• A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.

Details

• E88.3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.

• The 2023 edition of ICD-10-CM E88.3 became effective on October 1, 2022.

• This is the American ICD-10-CM version of E88.3 – other international versions of ICD-10 E88.3 may differ.